- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02946697
A Culturally Sensitive Social Support Intervention (JLA)
October 14, 2024 updated by: M.D. Anderson Cancer Center
This study is a randomized controlled trial (RCT) to assess the impact of a culturally based social support program (i.e.
Joy Luck Academy, JLA) among Chinese American breast cancer survivors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized controlled trial (RCT) to test the health benefits of an education and peer mentor support intervention.
Chinese American breast cancer survivors who have completed primary treatment will be randomly assigned to either the intervention group or a control group to receive enhanced usual care while waiting for the JLA.
Health outcomes are assessed at baseline, immediately post intervention, and 1 and 4 months follow-ups.
Study Type
Interventional
Enrollment (Actual)
168
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 91776
- Herald Cancer Association
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion criteria:
- self-identified to be comfortable speaking Chinese (Mandarin or Cantonese)
- having a first breast cancer diagnosis of stages 0-III
- having completed primary treatment (surgery, chemotherapy, or radiotherapy) within the last 36 months
Exclusion criteria:
- unable to read or speak Chinese (Mandarin or Cantonese)
- breast cancer diagnosis of stage IV
- live outside of the LA area
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Enhanced care and wait-list control group
Participants in the control group will receive enhanced usual care while waiting for the JLA program.
Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment.
Participants will be asked to read through the booklet individually.
|
|
|
Experimental: Social support intervention group
The intervention is a 7-week program includes educational and peer mentoring support components.
The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image.
The peer-support component assigns each participant with a mentor who is a breast cancer survivor.
They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
|
The social support intervention is a 7-week program includes educational and peer mentoring support components.
The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image.
The peer-support component assigns each participant with a mentor who is a breast cancer survivor.
They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Quality of life as assessed by Functional Assessment of Cancer Therapy Scale (FACT)
Time Frame: Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in depressive symptoms as assessed by CES-D
Time Frame: Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
Depressive symptoms will be measured with the Chinese short-form version (Boey, 1999) of the Center for Epidemiologic Studies Depression Scale (CES-D; Radloff, 1977) as well as two additional items ("I don't want to have contact with people, socialize, or go out at all" and "I have thought about hurting myself") from the Chinese American Depression Scale (CADS-9).
|
Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
|
Change in positive affect as assessed by the PANAS
Time Frame: Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
|
|
Change in fatigue as assessed by FACIT
Time Frame: Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
A short-version (i.e.
6-item) of Functional Assessment of Chronic Illness Therapy-Fatigue scale was used.
|
Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
|
Change in stress as assessed by the Perceived stress scale (PSS)
Time Frame: Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
Baseline before intervention and immediately, 1 month, and 4 months after the intervention
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in cortisol slope
Time Frame: Baseline before intervention and immediately
|
Baseline before intervention and immediately
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Qian Lu, PhD; MD, University of Houston
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
October 14, 2024
Study Completion (Actual)
October 14, 2024
Study Registration Dates
First Submitted
October 25, 2016
First Submitted That Met QC Criteria
October 25, 2016
First Posted (Estimated)
October 27, 2016
Study Record Updates
Last Update Posted (Actual)
October 16, 2024
Last Update Submitted That Met QC Criteria
October 14, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PA18-0280
- R01CA180896 (U.S. NIH Grant/Contract)
- 16402-02 (Other Identifier: University of Houston)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.